Price Alert

CytomX Therapeutics Inc. (CTMX)

NASDAQ: CTMX · Real-Time Price · USD

2.28

0.18 (8.57%)

At close: Sep 05, 2025, 3:59 PM

2.30

0.88%

After-hours: Sep 05, 2025, 06:51 PM EDT

CytomX Therapeutics Statistics

Share Statistics

CytomX Therapeutics has 164.91M shares outstanding. The number of shares has increased by 101.68% in one year.

Shares Outstanding	164.91M
Shares Change (YoY)	101.68%
Shares Change (QoQ)	96.68%
Owned by Institutions (%)	51.85%
Shares Floating	120.75M
Failed to Deliver (FTD) Shares	53
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 25.14M, so 15.24% of the outstanding shares have been sold short.

Short Interest	25.14M
Short % of Shares Out	15.24%
Short % of Float	15.81%
Short Ratio (days to cover)	5.61

Valuation Ratios

The PE ratio is 2.73 and the forward PE ratio is -6.77. CytomX Therapeutics's PEG ratio is 0.

PE Ratio	2.73
Forward PE	-6.77
PS Ratio	0.63
Forward PS	7.5
PB Ratio	-190.73
P/FCF Ratio	-1
PEG Ratio	0

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for CytomX Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.25, with a Debt / Equity ratio of -20.58.

Current Ratio	1.25
Quick Ratio	1.25
Debt / Equity	-20.58
Debt / EBITDA	0.35
Debt / FCF	-0.11
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$1.16M
Profits Per Employee	$267.81K
Employee Count	119
Asset Turnover	1.15
Inventory Turnover	n/a

Taxes

Income Tax	224K
Effective Tax Rate	0.7%

Stock Price Statistics

The stock price has increased by 90% in the last 52 weeks. The beta is 2.17, so CytomX Therapeutics's price volatility has been higher than the market average.

Beta	2.17
52-Week Price Change	90%
50-Day Moving Average	2.24
200-Day Moving Average	1.42
Relative Strength Index (RSI)	57.29
Average Volume (20 Days)	2,626,427

Income Statement

In the last 12 months, CytomX Therapeutics had revenue of 138.1M and earned 31.87M in profits. Earnings per share was 0.38.

Revenue	138.1M
Gross Profit	138.1M
Operating Income	25M
Net Income	31.87M
EBITDA	26.76M
EBIT	25M
Earnings Per Share (EPS)	0.38

Full Income Statement

Balance Sheet

The company has 38.05M in cash and 9.38M in debt, giving a net cash position of 28.67M.

Cash & Cash Equivalents	38.05M
Total Debt	9.38M
Net Cash	28.67M
Retained Earnings	-691.58M
Total Assets	175.06M
Working Capital	125.4M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -86.23M and capital expenditures -310K, giving a free cash flow of -86.54M.

Operating Cash Flow	-86.23M
Capital Expenditures	-310K
Free Cash Flow	-86.54M
FCF Per Share	-1.02

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of 18.1% and 23.08%.

Gross Margin	100%
Operating Margin	18.1%
Pretax Margin	23.24%
Profit Margin	23.08%
EBITDA Margin	19.38%
EBIT Margin	18.1%
FCF Margin	-62.66%

Dividends & Yields

CTMX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for CTMX is $5, which is 119.3% higher than the current price. The consensus rating is "Buy".

Price Target	$5
Price Target Difference	119.3%
Analyst Consensus	Buy
Analyst Count	3

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	0.87
Piotroski F-Score	4